Semaglutide is a medication primarily used for managing type 2 diabetes, but its effects on the body can also influence uric acid levels
Enhanced delivery of topically-applied formulations following skin pre-treatment with a hand-applied, plastic microneedle array
It all starts with one prompt in Claude Code: What Nimble found: $52-94B market (2025), projected $132-185B by 2033 Eli Lilly became the first $1T healthcare company on tirzepatide momentum Novo Nordisk CEO replaced after CagriSema missed its target Pipeline: retatrutide (triple agonist, ~24% weight loss), orforglipron (first unrestricted oral), amycretin (next-gen) FDA cracking down on compounded semaglutide Hims & Hers stock collapsed Medicare Part D obesity coverage starting July 2026 40M new beneficiaries Result: 82 cross-linked wiki pages : 18 companies, 10 drugs, 10 clinical trials, 7 people, 6 markets, 5 regulatory events
The MRS metabolite estimates were not known at the time of clinical outcome characterization
#MDPI #OpenAccess #Biomedicines #Probenecid #OAT #Pannexin1 #TRPV2 #CentralNervousSystem #Neuroinflammation #Epilepsy #NeurodegenerativeDiseases To view or add a comment, sign in SURPASS-CVOT sets a new standard for type 2 diabetes outcomes trials by including an active comparator (dulaglutide) which has already been shown to be cardioprotective
Retatrutide is one of the newest investigational peptides being explored in metabolic research
